Altimmune - $100k + YOLO - The MASH Sleeping Giant, the train is leaving the station - Stock hit $500m market cap today!

As English is not my first language, I have used Gemini to help me. But you know what, see the positions first, cause that is all you degens care about https://preview.redd.it/24e9squoyyeg1.png?width=1080&format=png&auto=webp&s=1dfe11f8b6fb01b28a489a845604ff4176e21bb3 and now the part which 99% of you guys wont read: So I have been digging through the biotech trash heap looking for gold, and I think I found the only ticker that Mr. Market is completely sleeping on. We are talking about **Altimmune ($ALT)**. If you’ve been watching the GLP-1 space (Lilly, Novo), you know the "fat loss" trade is crowded. But $ALT just pivoted to the holy grail: **MASH (liver disease) + Weight Loss.** And the setup right now is looking like a powder keg waiting for a match. Here is the DD. # 1. The Data is absolute fire (FDA Agrees) The market punished this thing last year because they wanted "just another weight loss drug." $ALT gave them something better: **Pemvidutide.** * **BTD CONFIRMED:** As of Jan 5, 2026, the FDA granted them **Breakthrough Therapy Designation (BTD)** for MASH. This is huge. It means the FDA sees "substantial improvement" over existing therapies. This is also means chances of approval are now over 75%, FDA wants this drug * **The Kicker:** Unlike Madrigal’s drug (Rezdiffra) which just treats the liver, $ALT’s drug shreds fat too. Patients hit **7.5% weight loss at 48 weeks** on the high dose, and the chart showed *no plateau* (meaning they were still losing weight). It’s a two-for-one special: Fix the liver, lose the gut. # 2. The "For Sale" Sign is Blinking This is the most bullish part. Look at the C-Suite changes. They aren't building a 20-year dynasty; they are dressing the bride for a wedding. * **New CEO (Jan 2026):** Jerry Durso. Who is he? He was the CEO of Intercept Pharmaceuticals. **He literally just sold Intercept to Alfasigma.** He knows exactly how to package a liver drug for a buyout. * **New CFO (Nov 2024):** Greg Weaver. This guy was the CFO at Sirna (sold to Merck) and ILEX (sold to Genzyme). * **Translation:** You don't hire a liquidation squad if you plan to run independent trials for the next decade. # 3. Valuation is a Joke (The Value Play) Let’s look at the comps. This is why it’s the best value on the board. * **Madrigal ($MDGL):** Multi-Billion market cap. (Commercial stage, but expensive). * **Viking ($VKTX):** \~$8B+ market cap. * Novo also got some company in this space for billions * **Altimmune ($ALT):** **\~$450M - $550M Market Cap.** It is trading at cash + a handshake. If this gets even *half* the valuation of its peers, it’s a multi-bagger. The Phase 3 setup is fully aligned with the FDA. The ship is loaded. # 4. The Catalyst & The Risk * **The Hype:** The stock started heating up at the JPM Healthcare Conference (Jan 2026). Big Pharma is swimming in cash and looking for MASH assets because their patents are expiring. * **The Risk (The Bear Case):** Cash. They have \~$210M (as of late 2025). Phase 3 is expensive. * *Scenario A:* They dilute. Stock dips, we cry, then it recovers. * *Scenario B:* Partnership (Non-dilutive cash). Stock moons. * *Scenario C:* Buyout. We retire. # Summary They have the **Data** (BTD granted), they have the **Management** (literally hired guys who sell companies), and they have the **Market Cap** (insanely low compared to peers). This isn't a pure obesity play anymore; it's the leading **MASH play** that makes you skinny. **TL;DR:** * **Ticker:** $ALT * **Catalyst:** FDA Breakthrough Therapy Designation + Phase 3 start. * **Upside:** 3-5x to catch up to peer valuations. * **Risk:** Cash burn/Dilution (unless they partner/sell first). * **Prediction:** Jerry Durso didn't take this job to work a 9-5. He took it to sign a deal. bonus - 21% SI Not financial advice, but this could 2x to 10x , who the hell knows, but is should fly baby fly